Pre-made Dostarlimab benchmark antibody ( Whole mAb, anti-PDCD1 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-154
Anti-PDCD1 therapeutic antibody (Pre-made Dostarlimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody medication used for the treatment of endometrial cancer.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-PDCD1 therapeutic antibody (Pre-made Dostarlimab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||AnaptysBio;European Network of Gynaecological Oncological Trial Groups;GlaxoSmithKline;TESARO|
|Conditions Approved||Endometrial cancer;Solid tumours|
|Conditions Active||Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Non-small cell lung cancer;Breast cancer;Cervical cancer;Liver cancer;Malignant melanoma;Neuroendocrine tumours;Pancreatic cancer;Rectal cancer;Small cell lung cancer;Squamous cell cancer|